Clarithromycin

Cat-Scratch Disease, Sinusitis, Whooping Cough + 14 more
Treatment
21 FDA approvals
20 Active Studies for Clarithromycin

What is Clarithromycin

ClarithromycinThe Generic name of this drug
Treatment SummaryClarithromycin is an antibiotic derived from erythromycin. It works by inhibiting the production of proteins in bacteria, which prevents them from multiplying. Depending on the concentration of the drug, it can either stop the bacteria from growing or kill them.
Biaxinis the brand name
image of different drug pills on a surface
Clarithromycin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Biaxin
Clarithromycin
1991
187

Approved as Treatment by the FDA

Clarithromycin, also known as Biaxin, is approved by the FDA for 21 uses which include Bacterial Infections and Otitis Media (OM) .
Bacterial Infections
Otitis Media (OM)
prophylaxis of Mycobacterial infection
Mycobacterial Infections
uncomplicated skin and subcutaneous tissue bacterial infections
Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)
Acute maxillary sinusitis
Duodenal ulcer caused by helicobacter pylori
Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Amoxicillin
Tonsillitis streptococcal
Streptococcal Pharyngitis
Bronchitis, Chronic
Urinary Tract Infection (UTI)
HIV
Otitis
Duodenal Ulcer
Used to treat Duodenal ulcer caused by helicobacter pylori in combination with Amoxicillin
Mycobacterium Infections
Sinusitis
Community Acquired Pneumonia (CAP)
Bacterial Infections
Tuberculosis
Tonsillitis

Effectiveness

How Clarithromycin Affects PatientsClarithromycin is a type of antibiotic used to treat a range of bacteria, including many common types such as Staphylococcus aureus, Haemophilus influenzae, Mycoplasma, and Chlamydia. It has been found to be as effective or more effective than erythromycin against certain bacteria. Clarithromycin usually stops bacteria from reproducing, but can sometimes kill them.
How Clarithromycin works in the bodyClarithromycin works by entering bacteria cells and binding to a part of their ribosomes, which are responsible for making proteins. This binding blocks the bacteria's ability to make proteins, preventing it from reproducing and causing infection. Clarithromycin also stops enzymes that break down medicine in the liver, making it more effective.

When to interrupt dosage

The recommended dosage of Clarithromycin is contingent upon the determined condition, for instance Mycobacterium Infections, Lyme Disease and Bacterial Infections. The amount may vary as per the administration technique (e.g. Powder, for suspension or Capsule; Kit; Tablet) featured in the table below.
Condition
Dosage
Administration
Mycobacterium Infections
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Bacterial Infections
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Tuberculosis
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Bacterial Endocarditis
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Duodenal Ulcer
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
HIV
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Bronchitis, Chronic
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Bacterial Endocarditis
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Community Acquired Pneumonia (CAP)
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Streptococcal Pharyngitis
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Cat-Scratch Disease
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Sinusitis
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Whooping Cough
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Lyme Disease
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Urinary Tract Infection (UTI)
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Tonsillitis
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral
Otitis
, 500.0 mg, 250.0 mg, 250.0 mg/mL, 125.0 mg/mL, 1000.0 mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Kit, Tablet - Oral, Tablet, Tablet, coated, Tablet, coated - Oral, For suspension, For suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule; Capsule, delayed release; Kit; Tablet, Capsule; Capsule, delayed release; Kit; Tablet - Oral, Kit - Oral

Warnings

Clarithromycin Contraindications
Condition
Risk Level
Notes
Liver Dysfunction
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Jaundice, Obstructive
Do Not Combine
There are 20 known major drug interactions with Clarithromycin.
Common Clarithromycin Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Major
The metabolism of (R)-warfarin can be decreased when combined with Clarithromycin.
(S)-Warfarin
Major
The metabolism of (S)-Warfarin can be decreased when combined with Clarithromycin.
1,2-Benzodiazepine
Major
The metabolism of 1,2-Benzodiazepine can be decreased when combined with Clarithromycin.
3,5-diiodothyropropionic acid
Major
The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Clarithromycin.
5-androstenedione
Major
The metabolism of 5-androstenedione can be decreased when combined with Clarithromycin.
Clarithromycin Toxicity & Overdose RiskSymptoms of clarithromycin toxicity include diarrhea, nausea, bad taste, indigestion, stomach pain, and temporary hearing loss. In some cases, colitis, allergic reactions (from hives to anaphylaxis), liver damage, and tooth discoloration have been reported. Animal studies have also linked clarithromycin to fetal abnormalities such as heart defects, cleft palate and slow growth. Additionally, this drug may cause a prolonged QT interval.
image of a doctor in a lab doing drug, clinical research

Clarithromycin Novel Uses: Which Conditions Have a Clinical Trial Featuring Clarithromycin?

160 active clinical trials are currently exploring the potential of Clarithromycin to provide relief for Pertussis, HIV and Urinary Tract Infection (UTI).
Condition
Clinical Trials
Trial Phases
Mycobacterium Infections
0 Actively Recruiting
Whooping Cough
0 Actively Recruiting
HIV
157 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
Urinary Tract Infection (UTI)
8 Actively Recruiting
Phase 1, Phase 3, Phase 4, Phase 2
Streptococcal Pharyngitis
0 Actively Recruiting
Tonsillitis
0 Actively Recruiting
Community Acquired Pneumonia (CAP)
5 Actively Recruiting
Not Applicable, Phase 1, Phase 3
Otitis
0 Actively Recruiting
Cat-Scratch Disease
0 Actively Recruiting
Sinusitis
0 Actively Recruiting
Bronchitis, Chronic
0 Actively Recruiting
Bacterial Infections
0 Actively Recruiting
Bacterial Endocarditis
1 Actively Recruiting
Not Applicable
Duodenal Ulcer
0 Actively Recruiting
Bacterial Endocarditis
0 Actively Recruiting
Tuberculosis
0 Actively Recruiting
Lyme Disease
3 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable

Clarithromycin Reviews: What are patients saying about Clarithromycin?

4.7Patient Review
7/25/2022
Clarithromycin for infection caused by bacteria
I was in a lot of pain from an untreated bacterial infection, and these tablets were worth their weight in gold to me. I don't care about the side effects; they made me better. If you're bothered about the side effects, then you must not have been in as much pain as I was. Get a life—thank goodness you're alive and these tablets made you better instead of complaining about the side effects!
3.3Patient Review
7/19/2022
Clarithromycin for Acute Infection of the Nose, Throat or Sinus
I got tonsillitis, then my doctor recommended this Clarithromycine antibiotic. On the first day, the pain in my tonsils lessened. However, I didn't like its side effect; whenever I ate and took the medicine, I felt stomach pain and vomitied every two hours.
2.3Patient Review
7/3/2022
Clarithromycin for Infection of the Middle Ear caused by Streptococcus
After only three days of taking this antibiotic, I experienced a range of awful side effects, including but not limited to: jitters, watery diarrhea, nausea, fatigue, headache and brain fog. Never have I felt this bad before; I had to stop taking the medication and will never take it again. It's unbelievable that this is on the market.
2.3Patient Review
6/15/2022
Clarithromycin for Middle Ear Infection
I was given this medication because of an ear infection after having the flu. On the first day, I had severe stomach pain for around 20 minutes. However, what really bothered me from the second day onward was the bitter taste in my mouth that didn't go away for more than 8 hours after taking the medication. Today is my third day, and the bitter saliva is still bothering me.
2.3Patient Review
10/11/2022
Clarithromycin for infection caused by bacteria
I found the recommended dosage of this drug to be far too much for my system. I had severe reactions including joint and muscle pain, nausea, and insomnia. If you've ever had a reaction to antibiotics in the past, I would recommend avoiding this medication entirely.
2.3Patient Review
4/16/2022
Clarithromycin for Acute Infection of the Nose, Throat or Sinus
I never want to take this again. It sent my anxiety levels through the roof and I would rather be in pain than deal with the side effects.
1.3Patient Review
1/9/2022
Clarithromycin for Acute Maxillary Sinus H. Influenzae Bacteria Infection
I unfortunately experienced a range of adverse effects from taking this medication. I would advise against it based on my personal experience.
1.3Patient Review
4/25/2022
Clarithromycin for Middle Ear Infection
The side effects of Klacid were so bad that I couldn't even finish the course of antibiotics. I experienced insomnia, restlessness, and awful abdominal cramps and nausea. I would never use this medication again.
1Patient Review
11/10/2022
Clarithromycin for infection caused by bacteria
I had some nasty side effects after only taking this twice. I wouldn't recommend it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about clarithromycin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is clarithromycin stronger than amoxicillin?

"Clarithromycin seems to work as well as amoxicillin/clavulanate against acute maxillary sinusitis, and it may cause fewer problems with upset stomach."

Answered by AI

What are the most common side effects of clarithromycin?

"Some potential side effects of this medication include diarrhea, nausea, vomiting, stomach pain, heartburn, gas, a change in taste, and headache."

Answered by AI

Is clarithromycin and amoxicillin the same?

"This product contains two different types of antibiotics: amoxicillin, which is a penicillin-type antibiotic, and clarithromycin, which is a macrolide-type antibiotic. These antibiotics work by stopping the growth of bacteria, and they are effective against only bacterial infections."

Answered by AI

What is clarithromycin antibiotic used for?

"This drug is used to treat bacterial infections by killing the bacteria. It is also used in tandem with other drugs to treat ulcers in the duodenum, which are caused by the bacteria H. pylori. Additionally, this medication is taken to prevent and treat infection by the Mycobacterium avium complex."

Answered by AI

Clinical Trials for Clarithromycin

Image of University of Alabama at Birmingham in Birmingham, United States.

Olfactory Training for HIV

18+
All Sexes
Birmingham, AL
The goal of this study is to examine two types of olfactory interventions (olfactory training vs overnight odor diffuser) in adults with HIV. The two research questions are: 1. Determine if participants find the intervention acceptable and assess feasibility of the study. 2. Determine if the intervention improves olfactory function and cognitive function. Participants will come to our office and be administered the baseline battery of questions including olfactory and cognitive performance tests. Then they will be randomized and sent home with one of the two interventions (below) in which they will engage in it for 8 weeks, after which they come back to our office for the posttest battery of questions including olfactory and cognitive performance test. 1. Olfactory Training at Home -- 4 scents in which they will smell twice a day for 8 weeks. 2. Overnight Diffuser Group -- a single scent diffuser that participants will turn on while they sleep and use for 8 weeks.
Phase < 1
Waitlist Available
University of Alabama at Birmingham
Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA
This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.
Waitlist Available
Has No Placebo
Los Angeles General Medical CenterHayoun Lee, PhD
Image of University of North Carolina in Chapel Hill, United States.

MGD020 + MGD014 for HIV

18 - 65
All Sexes
Chapel Hill, NC
This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given. In this study, participants will be randomly assigned to one of three groups. All participants receive MGD014 and MGD020, given sequentially as infusions through an IV for 4 doses. Participants in one group (group A) receive only MGD014 and MGD020. Participants in another group (group B) will stop taking their ART therapy for up to 8 weeks (a temporary treatment interruption (TTI)) while receiving MGD014 and MGD020. Participants in the third group (group C) receive Vorinostat in addition to MGD014 and MGD020. Total time of participation is about 8 months and involves 13 or 18 visits, depending on group assignment.
Phase 1
Recruiting
University of North CarolinaCynthia L. Gay, MD
Have you considered Clarithromycin clinical trials? We made a collection of clinical trials featuring Clarithromycin, we think they might fit your search criteria.Go to Trials
Have you considered Clarithromycin clinical trials? We made a collection of clinical trials featuring Clarithromycin, we think they might fit your search criteria.Go to Trials
Image of UCSF in San Francisco, United States.

N-803 for HIV

18 - 70
All Sexes
San Francisco, CA
Even though HIV medicine stops the virus from making more copies of itself, the virus remains in the body by hiding inside of immune cells. This hidden virus is referred to as the "latent reservoir." Researchers on this team are studying whether stimulating the immune system can change the nature of the latent reservoir and if this could help people control HIV without the need to take regular HIV medicine. This study is testing a drug called N-803. N-803 is also known as Interleukin-15 or "IL-15", a powerful and long lasting protein that can affect the immune system by stimulating immune cells such as CD8+ T cells and natural killer (NK) cells. CD8+ T cells and NK cells are both crucial for eliminating infected cells. The drug is FDA-approved for the treatment of bladder cancer, but in this study the drug is being used experimentally for HIV.
Phase 2
Waitlist Available
UCSF
Image of Alabama CRS (Site ID: 31788) in Birmingham, United States.

Dasatinib + Quercetin for HIV

18+
All Sexes
Birmingham, AL
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Phase 2
Waitlist Available
Alabama CRS (Site ID: 31788) (+26 Sites)
Image of Yale University in New Haven, United States.

DynamiCare + Patient Navigation for Stimulant Use Disorder

18+
All Sexes
New Haven, CT
Justice-involved individuals face disproportionately high rates of stimulant use disorder and HIV, along with disrupted access to HIV treatment and prevention services like ART and PrEP. Contingency management (CM) is the most effective intervention for stimulant use, but its use in justice-involved populations has been limited by logistical and structural barriers. DynamiCare is an FDA-approved mobile app that delivers behavioral CM and has shown promise in reducing stimulant use, but its impact on HIV-related outcomes remains unknown. The RESTORE study (Recovery and Engagement for Stimulant Users on Re-entry) will evaluate whether combining DynamiCare with patient navigation (DynamiCare-plus) improves PrEP/ART initiation and reduces stimulant use among individuals recently released from justice settings. The R61 phase will assess feasibility, acceptability, and preliminary effectiveness among 40 participants. If milestones are met, the R33 phase will scale to a randomized controlled trial with 252 participants to assess effectiveness, implementation, and cost. This scalable, mobile approach has the potential to address a critical gap in care for a highly vulnerable population.
Waitlist Available
Has No Placebo
Yale University (+1 Sites)Ank Nijhawan, MD
Have you considered Clarithromycin clinical trials? We made a collection of clinical trials featuring Clarithromycin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security